Odontella
Creating and developing foods of the future in France, based on microalgae and marine algae, formulated and patented by the company.
| Date | Investors | Amount | Round |
|---|---|---|---|
$800k | Seed | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 544 % | (51 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1745 %) | (410 %) | (656 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1410 %) | (282 %) | (678 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Odontella is a food technology company operating at the intersection of agritech and biotechnology, focused on developing sustainable food alternatives derived from marine microalgae. Founded in 2016 and headquartered in Bordeaux, France, the company leverages patented technology to harness the nutritional and functional properties of *Odontella aurita*, a marine diatom. The company’s foundation is built upon patents from Dr. Pierre Calleja, a specialist in microalgae biotechnology.
The company's core business involves the creation and commercialization of food products based on this unique microalgae, which has been approved as a Novel Food by European authorities. Odontella targets the growing market of consumers seeking plant-based, healthy, and environmentally friendly food options, including vegans and flexitarians. Its business model appears to be B2B, collaborating with food retailers to bring its products to market, as well as selling its own inventory.
Odontella’s flagship product is a plant-based salmon substitute named Solmon, which launched in France in 2018. This product is designed to replicate the taste, appearance, texture, and nutritional profile of conventional salmon. It is rich in marine-based vegetable proteins, Omega-3 fatty acids (specifically EPA), and other beneficial compounds like carotenoids. The primary ingredient, *Odontella aurita*, provides these health benefits, offering a solution to the increasing demand for Omega-3s without contributing to the over-exploitation of fisheries. Beyond the salmon alternative, the company holds a portfolio of at least seven patents for a range of food products, including beverages and prepared meals.
Since its inception, Odontella has progressed through several funding stages, including an accelerator program, a grant, equity crowdfunding, and seed rounds in 2017, followed by a Later Stage VC round in 2022. Keywords: foodtech, alternative protein, microalgae, plant-based seafood, salmon substitute, Odontella aurita, marine biotechnology, sustainable food, vegan products, agritech, blue economy, Solmon, EPA, Omega-3, food innovation, Novel Food, seafood alternative, plant-based salmon, food formulation, diatoms